NCT06812104View on ClinicalTrials.gov

Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2028

Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
DRUG

KK2845_1

KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).

DRUG

KK2845_2

KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).

DRUG

KK2845_3

KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).

DRUG

KK2845_4

KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).

Trial Locations (1)

060-8648

RECRUITING

Hokkaido University Hospital, Sapporo

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY